ReviewJournal of cellular physiology2019
Tumor suppressors BTG1 and BTG2: Beyond growth control.
Review in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 1 synthesis or guideline pooled it, 236 citations in OpenAlex.
- Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis.Current medical science · 2020Pooled it
- Research progress on BTG2 in non‑tumor diseases (Review).International journal of molecular medicine · 2026Review
- BTG1 Mutation Correlates with Inferior Prognosis in Diffuse Large B-Cell Lymphoma.Cancer research and treatment · 2026Article
- A network-based deep learning model integrating subclonal architecture for therapy response prediction in cancer.Cell reports methods · 2026Article
- Dynamic uterine microenvironment drives endometrial adenocarcinoma carcinogenesis and progression.Communications biology · 2026Article
- Metabolic and transcriptional plasticity supports CD8Immunity · 2026Article
- Btg2 inhibits Fmo1 UFMylation thus exacerbating ferroptosis and apoptosis in hepatic ischemia-reperfusion injury.Nature communications · 2026Article
- Chemotherapy-Induced Oral Mucosal Injury Is Defined by p53 Activation, Cell Cycle Arrest and Diverse Epithelial Progenitor Dynamics.bioRxiv : the preprint server for biology · 2026Article
- Anticancer agent FTY720 upregulates cell cycle regulator BTG2 via the SET/TAF-Iβ -PP2A-SMAD3 signaling pathway and induces G2/M arrest in leukemia.Genes & genomics · 2026Article
- The bladder cancer mEMBO reports · 2026Article
- Single-cell RNA sequencing reveals multiple pathways involving pulmonary immune and epithelial cells through which aryl hydrocarbon receptor activation attenuates acute respiratory distress syndrome.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Article
- Pre-Existing Th1 Immunity Outperforms Age in Predicting Antibody Responses to SARS-CoV-2 Inactivated Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- PC3/Tis21/BTG2 and BTG1 genes: regulators of the cell cycle and neurogenesis, as well as tumor suppressors in malignant brain tumors.Frontiers in cell and developmental biology · 2026Review
- Identification of an Immunotherapy-Associated CD1cInternational journal of women's health · 2026Article
- Distinct populations of lung capillary endothelial cells and their functional significance.Communications biology · 2025Article
- Targeting NADPH oxidase 2 suppresses the growth of esophageal squamous cell carcinoma by regulating BTG2 pathway.Discover oncology · 2025Article
- Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study.Molecular biomedicine · 2025Article
- Ferroptosis-related gene analysis revealing novel biomarkers and therapeutic targets in diffuse large B-cell lymphoma.Scientific reports · 2025Article
- Age-related microbiome metabolites alter RNA splicing and chromatin accessibility in the brain.bioRxiv : the preprint server for biology · 2025Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the identification of B-cell translocation gene 1 (BTG1) and BTG2 as antiproliferation genes more than two decades ago, their protein products have been implicated in a variety of cellular processes including cell division, DNA repair, transcriptional regulation and messenger RNA stability. In addition to affecting differentiation during development and in the adult, BTG proteins play an important role in maintaining homeostasis under conditions of cellular stress. Genomic profiling of B-cell leukemia and lymphoma has put BTG1 and BTG2 in the spotlight, since both genes are frequently deleted or mutated in these malignancies, pointing towards a role as tumor suppressors. Moreover, in solid tumors, reduced expression of BTG1 or BTG2 is often correlated with malignant cell behavior and poor treatment outcome. Recent studies have uncovered novel roles for BTG1 and BTG2 in genotoxic and integrated stress responses, as well as during hematopoiesis. This review summarizes what is currently known about the roles of BTG1 and BTG2 in these and other cellular processes. In addition, we will highlight the molecular mechanisms and biological consequences of BTG1 and BTG2 deregulation during cancer progression and elaborate on the potential clinical implications of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.